Clinical Trials Logo

FLT3-ITD Mutation clinical trials

View clinical trials related to FLT3-ITD Mutation.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT03135054 Active, not recruiting - AML Clinical Trials

Combination of Quizartinib and Omacetaxine Mepesuccinate for AML Carrying FLT3-ITD

Start date: October 1, 2017
Phase: Phase 2
Study type: Interventional

The study aims to test if combination of quizartinib (AC220) and omacetaxine mepesuccinate (OM, also known as homoharringtonine) results in durable composite complete remission (CRc) in patients with newly diagnosed or relapsed/refractory (R/R) acute myeloid leukemia (AML) carrying FLT3-ITD (Fms-Like Tyrosine Kinase 3 - Internal Tandem Duplication).